首页 / 院系成果 / 成果详情页

Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature  期刊论文  

  • 编号:
    59E6BDB7324B57F61D81E4FEC254828C
  • 作者:
    Ferdause, Jannatul#[1]Islam, Md Ariful[2];Ahmed, Nusrat[3];Kadir, A. K. M. Shafiul[4];Haque, Md Ariful*[5,6,7]
  • 语种:
    英文
  • 期刊:
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS ISSN:2210-2612 2024 年 120 卷 ; JUL
  • 收录:
  • 关键词:
  • 摘要:

    Introduction and importance: Radiation recall dermatitis (RRD) is a localized drug-induced inflammatory skin reaction occurring exclusively in a previously irradiated site months to years after discontinuation of ionizing radiation. The symptoms of RRD can range from mild redness to extensive dermatitis. Antineoplastic drugs such as doxorubicin, docetaxel, paclitaxel, and gemcitabine are most commonly associated with radiation recall reactions. These reactions can also occur with antibiotics and anti-tubercular drugs. Case presentation: A 38-years-old woman with hormone receptor-negative, HER2-positive inflammatory breast cancer (right), clinical stage cT4dN1Mx, received neoadjuvant chemotherapy with AC > TH protocol at 3 weeks intervals (Anthracycline-Doxorubicin plus Cyclophosphamide X 4 cycles, then docetaxel plus Trastuzumab X 4 cycles) followed by modified radical mastectomy followed by adjuvant locoregional radiotherapy. She received the 5th cycle and 6th cycle trastuzumab monotherapy just before the start of surgery and radiotherapy, respectively. After 1 month of completion of radiotherapy, during her seventh cycle of Trastuzumab monotherapy, she developed mild edema with erythematous change over the previously irradiated area with fever. A skin biopsy was taken to exclude any recurrence; however, no evidence of malignancy was found. Clinical discussion: We diagnosed it as a case of RRD. We managed her conservatively. Later, she was rechallenged with the same dose in subsequent cycles with systemic steroid coverage, which she tolerated very well, except for the reappearance of mild erythema following each cycle of maintenance dose of Trastuzumab. Conclusion: Radiation recall dermatitis is an extremely rare phenomenon; hence, an acquaintance of clinicians with this rare entity is essential for timely diagnosis and appropriate management.

  • 推荐引用方式
    GB/T 7714:
    Ferdause Jannatul,Islam Md Ariful,Ahmed Nusrat, et al. Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature [J].INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS,2024,120.
  • APA:
    Ferdause Jannatul,Islam Md Ariful,Ahmed Nusrat,Kadir A. K. M. Shafiul,&Haque Md Ariful.(2024).Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature .INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS,120.
  • MLA:
    Ferdause Jannatul, et al. "Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature" .INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS 120(2024).
  • 入库时间:
    2024/7/14 18:54:24
  • 更新时间:
    2024/12/23 22:30:07
  • 条目包含文件:
    文件类型: , 文件大小:
    正在加载全文
浏览次数:32 下载次数:0
浏览次数:32
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部